Login
$EVMN
$7.10 +$0.00 (0.0%) After hours

$EVMN 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader

05 Nov 2026 8-K: Regulation FD Disclosure

Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader

04 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an...

01 Oct 2026 8-K: Regulation FD Disclosure

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

23 Sep 2026 8-K: Regulation FD Disclosure

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

15 Sep 2026 8-K: Regulation FD Disclosure

Evommune Corporate Presentation September 2026 © Evommune, Inc.

09 Sep 2026 8-K: Regulation FD Disclosure; Other Events

‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

06 Aug 2026 8-K: Results of Operations and Financial Condition

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

30 Jul 2026 8-K: Regulation FD Disclosure

‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology

29 Jun 2026 8-K: Regulation FD Disclosure; Other Events

‑ Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2026, Evommune, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following two proposa...

07 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials

13 Apr 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements © Evommune, Inc. This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”). Statements contained in this presentation regarding matters that are not historical facts are “forward-looking state...

05 Mar 2026 8-K: Results of Operations and Financial Condition

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)

13 Feb 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 12, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a...

10 Feb 2026 8-K: Regulation FD Disclosure

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

11 Dec 2025 8-K: Results of Operations and Financial Condition

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU)

07 Nov 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Evommune, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support